Ocrelizumab
Treatment for Multiple Sclerosis
Typical Dosage: 600mg IV every 6 months (after initial loading doses)
Effectiveness
90%
Safety Score
45%
Clinical Trials
121
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
600mg IV every 6 months (after initial loading doses)
Time to Effect
3-6 months
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
20(Treat 20 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$65,000
Monitoring:$5,000
Side Effect Mgmt:$1,500
Total Annual:$71,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$118,000/QALY
QALYs Gained
1.2
Outcome-Based Costs
Cost per Responder
$84,117.65
Cost per Remission
$158,888.89
Comparison vs Interferon Beta-1a
Cost Difference
+$6,500/year
More expensive
QALY Difference
+0.25 QALYs
Better outcomes
Dominance
No dominance
Ocrelizumab Outcomes
for Multiple Sclerosis
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+85%
Remission Rate
+45%
Common Side Effects
Infusion reactions
+37%
Upper respiratory tract infections
+44%
Nasopharyngitis
+13%
Urinary tract infections
+10%
Oral herpes
+7%
Sources:
Active Clinical Trials
11 active trials recruiting for Ocrelizumab in Multiple Sclerosis
A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus
NCT07606521NOT YET RECRUITINGPHASE1
222 participants
INTERVENTIONAL
Started: Oct 1, 2026
A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations
NCT07597668ACTIVE NOT RECRUITINGPHASE1
180 participants
INTERVENTIONAL
Chelyabinsk, Russia +22 more
Started: Apr 16, 2025
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
NCT06847724ACTIVE NOT RECRUITINGPHASE3
183 participants
INTERVENTIONAL
Maitland, United States +40 more
Started: Jun 10, 2025
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
NCT06675955RECRUITINGPHASE3
500 participants
INTERVENTIONAL
Amiens Cedex1, France +43 more
Started: Dec 13, 2024
A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)
NCT06780150RECRUITING
842 participants
OBSERVATIONAL
Aachen, Germany +91 more
Started: Sep 26, 2024
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
NCT05285891ACTIVE NOT RECRUITINGPHASE4
123 participants
INTERVENTIONAL
New Haven, United States +12 more
Started: Feb 7, 2023
A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
NCT05906992RECRUITINGPHASE3
512 participants
INTERVENTIONAL
Poznan, Poland
Started: Jan 11, 2024
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
NCT04544436ACTIVE NOT RECRUITINGPHASE3
864 participants
INTERVENTIONAL
Cullman, United States +119 more
Started: Nov 26, 2020
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
NCT04548999ACTIVE NOT RECRUITINGPHASE3
769 participants
INTERVENTIONAL
Homewood, United States +146 more
Started: Dec 3, 2020
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004ACTIVE NOT RECRUITINGPHASE3
1.3K participants
INTERVENTIONAL
Phoenix, United States +235 more
Started: May 3, 2022
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis
NCT07483450ACTIVE NOT RECRUITINGPHASE4
60 participants
INTERVENTIONAL
Nanchang, China +16 more
Started: Jul 4, 2025
Completed Clinical Trials
8 completed trials for Ocrelizumab in Multiple Sclerosis
A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis
NCT03972306COMPLETEDPHASE1
134 participants
INTERVENTIONAL
Aurora, United States +17 more
Started: Aug 12, 2019
Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis
NCT04855617COMPLETED
122 participants
OBSERVATIONAL
Wellesley, United States +1 more
Started: Oct 26, 2020
Ocrelizumab Effects on the Metabolome in MS
NCT03873389COMPLETED
25 participants
OBSERVATIONAL
Baltimore, United States
Started: Jun 12, 2019
Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis
NCT03593590COMPLETED
1.71K participants
OBSERVATIONAL
Amstetten, Austria +157 more
Started: Nov 12, 2018
Mechanistic Study of Ocrevus
NCT04459988COMPLETED
35 participants
OBSERVATIONAL
Ann Arbor, United States
Started: Jul 1, 2020
This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)
NCT03599245COMPLETEDPHASE3
1.05K participants
INTERVENTIONAL
Buenos Aires, Argentina +158 more
Started: Jul 12, 2018
Short-term B-cell Depletion in Relapsing Multiple Sclerosis
NCT03853746COMPLETEDPHASE4
10 participants
INTERVENTIONAL
Baltimore, United States
Started: Apr 1, 2019
Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis
NCT03025269COMPLETED
30 participants
OBSERVATIONAL
Buffalo, United States
Started: Nov 15, 2017
Showing 20 of 138 total trials